Edmond de Rothschild Holding’s CRISPR Therapeutics CRSP Stock Holding History

Edmond de Rothschild Holding’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$34K	–	572
2025 Q1	$34K	Hold	1,000	–	–	﹤0.01%	484
2024 Q4	$39.4K	Hold	1,000	–	–	﹤0.01%	515
2024 Q3	$47K	Hold	1,000	–	–	﹤0.01%	528
2024 Q2	$54K	Buy	+1,000	New	+$57.8K	﹤0.01%	556
2022 Q4	–	Sell	-3,341	Closed	-$218K	–	792
2022 Q3	$218K	Hold	3,341	–	–	0.01%	449
2022 Q2	$203K	Buy	+3,341	New	+$196K	﹤0.01%	481
2022 Q1	–	Sell	-200	Closed	-$15K	–	818
2021 Q4	$15K	Sell	200 -15,676	-99%	-$1.37M	﹤0.01%	779
2021 Q3	$1.78M	Sell	15,876 -9,761	-38%	-$1.23M	0.04%	295
2021 Q2	$4.15M	Buy	25,637 +19,431	+313%	+$2.36M	0.1%	183
2021 Q1	$756K	Buy	6,206 +4,914	+380%	+$742K	0.02%	351
2020 Q4	$198K	Buy	+1,292	New	+$153K	0.01%	441

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Edmond de Rothschild Holding's CRSP Position: Q2 2025 in Review

Edmond de Rothschild Holding sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 1,000 shares — an estimated $34K sold.

Edmond de Rothschild Holding first reported a position in CRSP in Q4 2020 and held it in 11 quarters. The position peaked at $4.15M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

Edmond de Rothschild Holding reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
Edmond de Rothschild Holding sold 1,000 CRISPR Therapeutics shares in Q2 2025, an estimated $34K.
Edmond de Rothschild Holding first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 11 quarters.
Edmond de Rothschild Holding's CRISPR Therapeutics position peaked at $4.15M in Q2 2021.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2025, filed 12 Aug 2025.